Long term follow-up after haematopoietic stem cell transplantation for mucopolysaccharidosis type I-H : a retrospective study of 51 patients
© 2022. The Author(s)..
Mucopolysaccharidosis type I-H (MPS I-H) is a rare lysosomal storage disorder caused by α-L-Iduronidase deficiency. Early haematopoietic stem cell transplantation (HSCT) is the sole available therapeutic option to preserve neurocognitive functions. We report long-term follow-up (median 9 years, interquartile range 8-16.5) for 51 MPS I-H patients who underwent HSCT between 1986 and 2018 in France. 4 patients died from complications of HSCT and one from disease progression. Complete chimerism and normal α-L-Iduronidase activity were obtained in 84% and 71% of patients respectively. No difference of outcomes was observed between bone marrow and cord blood stem cell sources. All patients acquired independent walking and 91% and 78% acquired intelligible language or reading and writing. Intelligence Quotient evaluation (n = 23) showed that 69% had IQ ≥ 70 at last follow-up. 58% of patients had normal or remedial schooling and 62% of the 13 adults had good socio-professional insertion. Skeletal dysplasia as well as vision and hearing impairments progressed despite HSCT, with significant disability. These results provide a long-term assessment of HSCT efficacy in MPS I-H and could be useful in the evaluation of novel promising treatments such as gene therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Bone marrow transplantation - 58(2023), 3 vom: 09. März, Seite 295-302 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 14.03.2023 Date Revised 14.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41409-022-01886-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350067961 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350067961 | ||
| 003 | DE-627 | ||
| 005 | 20231226044120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-022-01886-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM350067961 | ||
| 035 | |a (NLM)36494569 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gardin, Antoine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long term follow-up after haematopoietic stem cell transplantation for mucopolysaccharidosis type I-H |b a retrospective study of 51 patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2023 | ||
| 500 | |a Date Revised 14.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Mucopolysaccharidosis type I-H (MPS I-H) is a rare lysosomal storage disorder caused by α-L-Iduronidase deficiency. Early haematopoietic stem cell transplantation (HSCT) is the sole available therapeutic option to preserve neurocognitive functions. We report long-term follow-up (median 9 years, interquartile range 8-16.5) for 51 MPS I-H patients who underwent HSCT between 1986 and 2018 in France. 4 patients died from complications of HSCT and one from disease progression. Complete chimerism and normal α-L-Iduronidase activity were obtained in 84% and 71% of patients respectively. No difference of outcomes was observed between bone marrow and cord blood stem cell sources. All patients acquired independent walking and 91% and 78% acquired intelligible language or reading and writing. Intelligence Quotient evaluation (n = 23) showed that 69% had IQ ≥ 70 at last follow-up. 58% of patients had normal or remedial schooling and 62% of the 13 adults had good socio-professional insertion. Skeletal dysplasia as well as vision and hearing impairments progressed despite HSCT, with significant disability. These results provide a long-term assessment of HSCT efficacy in MPS I-H and could be useful in the evaluation of novel promising treatments such as gene therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Iduronidase |2 NLM | |
| 650 | 7 | |a EC 3.2.1.76 |2 NLM | |
| 700 | 1 | |a Castelle, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Pichard, Samia |e verfasserin |4 aut | |
| 700 | 1 | |a Cano, Aline |e verfasserin |4 aut | |
| 700 | 1 | |a Chabrol, Brigitte |e verfasserin |4 aut | |
| 700 | 1 | |a Piarroux, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Roubertie, Agathe |e verfasserin |4 aut | |
| 700 | 1 | |a Nadjar, Yann |e verfasserin |4 aut | |
| 700 | 1 | |a Guemann, Anne-Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Tardieu, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Lacombe, Didier |e verfasserin |4 aut | |
| 700 | 1 | |a Robert, Matthieu P |e verfasserin |4 aut | |
| 700 | 1 | |a Caillaud, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Froissart, Roseline |e verfasserin |4 aut | |
| 700 | 1 | |a Leboeuf, Virginie |e verfasserin |4 aut | |
| 700 | 1 | |a Barbier, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Bouchereau, Juliette |e verfasserin |4 aut | |
| 700 | 1 | |a Schiff, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Fauroux, Brigitte |e verfasserin |4 aut | |
| 700 | 1 | |a Thierry, Briac |e verfasserin |4 aut | |
| 700 | 1 | |a Luscan, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a James, Syril |e verfasserin |4 aut | |
| 700 | 1 | |a de Saint-Denis, Timothée |e verfasserin |4 aut | |
| 700 | 1 | |a Pannier, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Gitiaux, Cyril |e verfasserin |4 aut | |
| 700 | 1 | |a Vergnaud, Estelle |e verfasserin |4 aut | |
| 700 | 1 | |a Boddaert, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Lascourreges, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Lemoine, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Bonnet, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Blanche, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Dalle, Jean-Hugues |e verfasserin |4 aut | |
| 700 | 1 | |a Neven, Bénédicte |e verfasserin |4 aut | |
| 700 | 1 | |a de Lonlay, Pascale |e verfasserin |4 aut | |
| 700 | 1 | |a Brassier, Anaïs |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d 1986 |g 58(2023), 3 vom: 09. März, Seite 295-302 |w (DE-627)NLM012638250 |x 1476-5365 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2023 |g number:3 |g day:09 |g month:03 |g pages:295-302 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41409-022-01886-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2023 |e 3 |b 09 |c 03 |h 295-302 | ||